Tessera
Folgen

beliu

@beliu.bsky.social

bcNyc. MD clinical neurophysiology. Pain medicine. Ph.D. in Drug Research, Development and Control UB

27 Posts37 Follower63 Folgt
Nature Medicine@natmed.nature.com · 6d ago

A first-in-human phase 1 study of an allogeneic, clinical-grade #iPSC-derived neural stem/progenitor cell product in patients with subacute complete #SpinalCordInjury demonstrates clinical feasibility and long-term safety.

An iPSC-derived neural progenitor cell therapy for subacute spinal cord injury: a phase 1 trial with long-term follow-up - Nature Medicine

A phase 1 trial evaluating the safety of iPSC-derived neural stem cell transplantation in subacute complete spinal cord injury, with 2–4 years of follow-up including MRI, neurological and functional assessments met its primary outcome.

dlvr.it

REMEDi4ALL@remedi4all.bsky.social · last wk.

💊 The MOI-A study, a REMEDi4ALL demonstrator project, is investigating the potential of losartan as a treatment for older adolescents and adults living with this rare genetic bone disorder. 👉 Learn more and find out how patients and families can get involved here: https://loom.ly/uaJ_YgA

Bild
European Medicines Agency@ema.europa.eu · 2w ago

📢 EMA recommends: 12 new medicines for approval, including one medicine for plaque psoriasis. Read more here: 🔗 www.ema.europa.eu/en/news/meet... 🧪 #PublicHealth #medsky #SciComm

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026 | European Medicines Agency (EMA)

Twelve new medicines recommended for approval; another eight medicines recommended for extension of their therapeutic indications

ema.europa.eu

WHO@who.int · 2w ago

Today marks 25 years of Research4Life by WHO. Since 2001, Research4Life has grown into one of the world's longest-running public-private partnerships for access to scientific knowledge. Learn more: bit.ly/4fM7vYp Together for health. #StandWithScience

This is a story about the power of scientific collaboration. 120+ countries. 12 000+ institutions. 250 000+ research resources. 25 years of Research4Life.
WHO@who.int · 3w ago

Protection against measles is dangerously low. Here’s the latest data: In 2025, 84% of children received their first dose of measles vaccine, and just 77% received a second dose. This is far below the 95% coverage needed to prevent outbreaks. This leaves children at risk worldwide.

Protection against measles is dangerously low. Only 77% children globally received 2 doses of measles vaccine. At least 95% coverage is needed to prevent outbreaks. The image shows the illustration of a baby's onesie depicting the percentages of the data.